Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
T-Mobile US
TMUS
|
+$530M |
| 2 |
AbbVie
ABBV
|
+$429M |
| 3 |
Boston Scientific
BSX
|
+$292M |
| 4 |
Snap
SNAP
|
+$241M |
| 5 |
Royalty Pharma
RPRX
|
+$223M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$327M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$295M |
| 3 |
AMTD
TD Ameritrade Holding Corp
AMTD
|
+$294M |
| 4 |
Sysco
SYY
|
+$209M |
| 5 |
Shopify
SHOP
|
+$176M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.65% |
| 2 | Healthcare | 19.7% |
| 3 | Consumer Discretionary | 10.81% |
| 4 | Financials | 9.9% |
| 5 | Communication Services | 8.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1051
Innoviva
INVA
$1.6B
| $1.67M | ﹤0.01% |
119,716
+57,648
| +93% | +$784K |
|
1052
NOV
NOV
$6.87B
| $1.67M | ﹤0.01% |
136,106
-1,798
| -1% | -$22.1K |
|
1053
ACM Research
ACMR
$4.48B
| $1.65M | ﹤0.01% |
79,437
+43,893
| +123% | +$720K |
|
1054
Corcept Therapeutics
CORT
$10B
| $1.65M | ﹤0.01% |
98,095
+78,205
| +393% | +$1.1M |
|
1055
John Wiley & Sons Class A
WLY
$2.85B
| $1.64M | ﹤0.01% |
42,056
-9,330
| -18% | -$356K |
|
1056
Mohawk Industries
MHK
$6.95B
| $1.6M | ﹤0.01% |
15,710
-12,201
| -44% | -$1.07M |
|
1057
PTC
PTC
$15.1B
| $1.59M | ﹤0.01% |
20,432
-394
| -2% | -$27.9K |
|
1058
Vanguard Total International Bond ETF
BNDX
$82B
| $1.58M | ﹤0.01% |
27,376
-10,400
| -28% | -$594K |
|
|
STSA
1059
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
| $1.57M | ﹤0.01% |
54,633
-9,743
| -15% | -$226K |
|
|
BSX.PRA
1060
DELISTED
Boston Scientific Corporation 5.50% Mandatory Convertible Preferred Stock, Series A
BSX.PRA
| $1.57M | ﹤0.01% |
+14,971
| New | +$1.6M |
|
1061
LKQ Corp
LKQ
$6.77B
| $1.56M | ﹤0.01% |
59,634
-7,577
| -11% | -$186K |
|
1062
Federal Realty Investment Trust
FRT
$10.8B
| $1.56M | ﹤0.01% |
18,295
-56,102
| -75% | -$4.53M |
|
1063
Rocket Pharmaceuticals
RCKT
$333M
| $1.54M | ﹤0.01% |
73,569
+5,579
| +8% | +$101K |
|
1064
Diamondback Energy
FANG
$55.9B
| $1.53M | ﹤0.01% |
36,630
+771
| +2% | +$31.5K |
|
1065
Insight Enterprises
NSIT
$3.84B
| $1.52M | ﹤0.01% |
30,885
+11,448
| +59% | +$564K |
|
1066
Lear
LEA
$7.42B
| $1.51M | ﹤0.01% |
13,886
-2,119
| -13% | -$211K |
|
1067
iShares 20+ Year Treasury Bond ETF
TLT
$42.9B
| $1.51M | ﹤0.01% |
9,218
-3,031
| -25% | -$499K |
|
1068
Robert Half
RHI
$4.19B
| $1.51M | ﹤0.01% |
28,538
+134
| +0.5% | +$6.36K |
|
1069
Copa Holdings
CPA
$5.62B
| $1.48M | ﹤0.01% |
29,284
-3,978
| -12% | -$184K |
|
1070
Nektar Therapeutics
NKTR
$2.3B
| $1.48M | ﹤0.01% |
4,246
-288
| -6% | -$89.9K |
|
1071
Napco Security Technologies
NSSC
$1.3B
| $1.47M | ﹤0.01% |
125,974
+99,162
| +370% | +$1.04M |
|
|
SEI
1072
Solaris Energy Infrastructure
SEI
$2.7B
| $1.46M | ﹤0.01% |
197,283
-663,876
| -77% | -$4.34M |
|
1073
Supernus Pharmaceuticals
SUPN
$2.73B
| $1.46M | ﹤0.01% |
61,615
+29,473
| +92% | +$651K |
|
1074
CACI
CACI
$10.8B
| $1.46M | ﹤0.01% |
6,740
-6,185
| -48% | -$1.48M |
|
1075
Kearny Financial
KRNY
$606M
| $1.4M | ﹤0.01% |
170,940
+7,216
| +4% | +$60.4K |
|
Similar funds
Janus Henderson Group's Q2 2020 Portfolio in Review
As of Q2 2020, Janus Henderson Group held 1,423 positions worth $178B, up 23% from $145B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Janus Henderson Group's Q2 2020 filing shows 132 new, 511 increased, 643 reduced and 125 closed positions. Its largest new stake was Royalty Pharma: 4,507,138 shares worth $219M. The largest sale was Boeing, an estimated $327M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q2 2020 buy was Royalty Pharma: 4,507,138 shares worth $219M.
- Janus Henderson Group added most to T-Mobile US in Q2 2020, an estimated $530M increase.
- Janus Henderson Group's biggest Q2 2020 reduction was Boeing, cutting an estimated $327M.
- Janus Henderson Group fully exited Allergan plc in Q2 2020, selling an estimated $128M.
- Janus Henderson Group's ten largest holdings make up 23% of its $178B portfolio in Q2 2020.
- Janus Henderson Group opened 132 new positions and closed 125 in Q2 2020.
- Janus Henderson Group's portfolio value rose 23% quarter-over-quarter to $178B.
Based on Janus Henderson Group's 13F filing for Q2 2020, filed 14 Aug 2020.